{
  "actions": [
    {
      "acted_at": "2001-12-11", 
      "committee": "House Committee on Energy and Commerce", 
      "references": [], 
      "status": "REFERRED", 
      "text": "Referred to the House Committee on Energy and Commerce.", 
      "type": "referral"
    }, 
    {
      "acted_at": "2001-12-28", 
      "in_committee": "House Committee on Energy and Commerce", 
      "references": [], 
      "subcommittee": "Health", 
      "text": "Referred to the Subcommittee on Health.", 
      "type": "referral"
    }
  ], 
  "amendments": [], 
  "bill_id": "hr3452-107", 
  "bill_type": "hr", 
  "committees": [
    {
      "activity": [
        "referral", 
        "in committee"
      ], 
      "committee": "House Energy and Commerce", 
      "committee_id": "HSIF"
    }, 
    {
      "activity": [
        "referral"
      ], 
      "committee": "House Energy and Commerce", 
      "committee_id": "HSIF", 
      "subcommittee": "Subcommittee on Health", 
      "subcommittee_id": "14"
    }
  ], 
  "congress": "107", 
  "cosponsors": [
    {
      "district": "14", 
      "name": "Eshoo, Anna G.", 
      "sponsored_at": "2001-12-11", 
      "state": "CA", 
      "thomas_id": "00355", 
      "title": "Rep", 
      "withdrawn_at": null
    }
  ], 
  "enacted_as": null, 
  "history": {
    "active": false, 
    "awaiting_signature": false, 
    "enacted": false, 
    "vetoed": false
  }, 
  "introduced_at": "2001-12-11", 
  "number": "3452", 
  "official_title": "To amend the Federal Food, Drug, and Cosmetic Act to improve the safety and efficacy of pharmaceuticals for children.", 
  "popular_title": null, 
  "related_bills": [
    {
      "bill_id": "s1789-107", 
      "reason": "identical", 
      "type": "bill"
    }
  ], 
  "short_title": "Best Pharmaceuticals for Children Act", 
  "sponsor": {
    "district": "8", 
    "name": "Greenwood, James C.", 
    "state": "PA", 
    "thomas_id": "00465", 
    "title": "Rep", 
    "type": "person"
  }, 
  "status": "REFERRED", 
  "status_at": "2001-12-11", 
  "subjects": [
    "Administrative procedure", 
    "Administrative remedies", 
    "Bioethics", 
    "Cancer", 
    "Chemotherapy", 
    "Child health", 
    "Clinical trials", 
    "Commerce", 
    "Congress", 
    "Congressional investigations", 
    "Congressional reporting requirements", 
    "Cost effectiveness", 
    "Department of Health and Human Services", 
    "Drug adulteration", 
    "Drug approvals", 
    "Drug industry", 
    "Drug interactions", 
    "Drug therapy", 
    "Drug utilization", 
    "Economic impact statements", 
    "Economics and public finance", 
    "Executive reorganization", 
    "Families", 
    "Federal advisory bodies", 
    "Federal aid to medical research", 
    "Finance and financial sector", 
    "Generic drugs", 
    "Government operations and politics", 
    "Government paperwork", 
    "Government publicity", 
    "Governmental investigations", 
    "Health", 
    "Health insurance", 
    "Health insurance industry", 
    "Hospital care", 
    "Human experimentation in medicine", 
    "Infants", 
    "Informed consent (Medical law)", 
    "Insurance premiums", 
    "Intellectual property", 
    "Labeling", 
    "Law", 
    "Medicaid", 
    "Medical economics", 
    "Medical ethics", 
    "Medical research", 
    "Minorities", 
    "Minority health", 
    "Parent and child", 
    "Patents", 
    "Pharmaceutical research", 
    "Pharmacists", 
    "Research grants", 
    "Science, technology, communications", 
    "Social welfare", 
    "Telephone", 
    "User charges"
  ], 
  "subjects_top_term": "Health", 
  "summary": {
    "as": "Introduced", 
    "date": "2001-12-11", 
    "text": "Best Pharmaceuticals for Children Act - Amends the Public Health Service Act to direct the Secretary of Health and Human Services, through the National Institutes of Health, to develop an annual list of approved drugs for which: (1) there is an approved or pending new drug application or no patent or market exclusivity protection; and (2) additional pediatric safety and effectiveness studies are needed. Directs the Secretary to award contracts to entities with appropriate experience for pediatric clinical trials of such drugs.Establishes a Food and Drug Administration (FDA) contract process for related labeling changes.Amends the Federal Food, Drug, and Cosmetic Act to: (1) eliminate the user fee waiver for pediatric supplements to a human drug application; (2) provide priority status for pediatric supplements; (3) include neonates within the definition of pediatric studies; (4) provide for dissemination of pediatric supplement information; and (5) set forth requirements for the additional six-month exclusivity period for new or already-marketed pediatric drugs.Directs the Secretary to establish an Office of Pediatric Therapeutics within the Office of the Commissioner of Food and Drugs, which shall coordinate all FDA pediatric activities.Includes within the purposes and activities of the Foundation for the National Institutes of Health the collection of funds for pediatric pharmacological research.Directs the Secretary to contract with the Institute of Medicine to review Federal regulations, reports, and support for research involving children, with particular attention to issues of compensation, informed consent, and risk/ benefits assessments in terms of research versus therapeutic treatment."
  }, 
  "titles": [
    {
      "as": "introduced", 
      "is_for_portion": false, 
      "title": "Best Pharmaceuticals for Children Act", 
      "type": "short"
    }, 
    {
      "as": "introduced", 
      "is_for_portion": false, 
      "title": "To amend the Federal Food, Drug, and Cosmetic Act to improve the safety and efficacy of pharmaceuticals for children.", 
      "type": "official"
    }
  ], 
  "updated_at": "2013-07-14T18:58:13-04:00"
}